Want to see IMNN full AI Analyst Report?
Top Page
Imunon
(NASDAQ:IMNN)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.50
▼(-0.66% Downside)
Action:Reiterated
Date:06/17/26
The score is primarily held down by weak financial performance (minimal revenue, large losses, and negative cash flow with added uncertainty from unusual TTM shifts) and a bearish technical trend. Offsetting factors include oversold technical conditions and supportive clinical/operational updates plus recent financing steps, but long timelines and funding risk remain key headwinds.
Positive Factors
Robust Phase II survival benefit
A durable, large Phase II OS signal materially de-risks the lead program by increasing the probability a pivotal trial can replicate benefit. This strengthens partner interest, licensing optionality and long-term commercial prospects, underpinning strategic value beyond short-term funding cycles.
Negative Factors
Near-zero revenue and large recurring losses
Persistent absence of product revenue and sizable net losses reflect a classic development-stage capital sink. Over time, continued losses erode equity cushions, constrain strategic flexibility and raise the bar for future financings or partner deals needed to sustain pivotal development and commercialization plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Robust Phase II survival benefit
A durable, large Phase II OS signal materially de-risks the lead program by increasing the probability a pivotal trial can replicate benefit. This strengthens partner interest, licensing optionality and long-term commercial prospects, underpinning strategic value beyond short-term funding cycles.
Read all positive factors
Imunon (IMNN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.68M
Dividend YieldN/A
Average Volume (3M)180.69K
Price to Earnings (P/E)―
Beta (1Y)-0.73
Revenue GrowthN/A
EPS Growth71.83%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.86
Shares Outstanding4,202,118
10 Day Avg. Volume410,974
30 Day Avg. Volume180,689
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.00Price Target Upside628.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.07
Revenue Forecast (FY)N/A
Imunon Business Overview & Revenue Model
Company Description
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifi...
How the Company Makes Money
Imunon primarily seeks to generate future revenue by advancing its internally developed product candidates through clinical development toward regulatory approval and, if approved, commercializing them directly and/or through partners; however, as...
Imunon Earnings Call Summary
Earnings Call Date:May 12, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call emphasized strong, potentially transformative clinical data (a ~14.7-month median OS benefit from OVATION II), clear enrollment momentum and favorable safety/translation signals, supported by an active plan to present additional data and to pursue investor-friendly financing. Counterbalancing these positives are a challenging capital market, a materially prolonged Phase III enrollment and readout timeline (last patient expected Q1 2029), and increased near-term cash burn driven by trial start-up costs. Management has outlined a restructuring and creative financing approach to conserve cash and limit dilution, and investor interest appears constructive. Overall, the clinical progress and enrollment momentum materially support upside potential, while financing and timeline risks remain meaningful near-term headwinds.Positive Updates
Robust Phase II Overall Survival Benefit
Final OVATION II Phase II data showed a clinically meaningful median overall survival benefit of ~14.7 months for IMNN-001 plus standard-of-care chemotherapy versus control (management noted the observed treatment effect grew from an earlier ~11 months to nearly 15 months across data refreshes).
Negative Updates
Challenging Capital Environment and Need for Bridge Financing
Management acknowledged a difficult biotech capital market and the need for targeted bridge financing to advance OVATION III. While seeking minimally dilutive or non-dilutive options and strategic partners, financing risk and potential dilution remain key near-term uncertainties.
Read all updates
Q1-2026 Updates
Positive
Negative
Robust Phase II Overall Survival Benefit
Final OVATION II Phase II data showed a clinically meaningful median overall survival benefit of ~14.7 months for IMNN-001 plus standard-of-care chemotherapy versus control (management noted the observed treatment effect grew from an earlier ~11 months to nearly 15 months across data refreshes).
Read all positive updates
Company Guidance
On the May 12, 2026 (FY2026 Q1) call Imunon gave concrete operational and financial guidance: OVATION III is a 500‑patient pivotal Phase III trial (IMNN‑001) with ~80 patients (16% of the total) called out for near‑term enrollment (management referenced ~80 patients by end‑2027 and ~80 patients ≈ one year from now) and an expected last‑patient in Q1 2029; two interim analyses are planned (first allowing early stopping for efficacy about 1–1.5 years after full enrollment, the second about a year later); they highlighted a 14.7‑month median OS benefit from OVATION II; financially Q1 R&D was $2.3M (vs $2.2M prior year), G&A was $22M in Q1 2026 (unchanged YoY), net cash used in operations was $4.0M (vs $2.8M prior year), and management expects a G&A/SG&A run‑rate of roughly $4.5–5.0M per quarter post‑reorganization while pursuing targeted bridge financings and cash‑conservation measures to extend runway.Imunon Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
32
Negative
Cash Flow
18
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 500.00K | 500.00K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 500.00K | 500.00K |
| EBITDA | -13.80M | -17.90M | -19.88M | -31.71M | -20.88M |
| Net Income | -14.49M | -18.62M | -19.51M | -35.90M | -20.77M |
Balance Sheet | |||||
| Total Assets | 12.29M | 9.72M | 21.92M | 43.98M | 74.05M |
| Cash, Cash Equivalents and Short-Term Investments | 8.78M | 5.87M | 15.70M | 32.75M | 49.39M |
| Total Debt | 1.01M | 1.14M | 1.62M | 6.27M | 6.63M |
| Total Liabilities | 5.23M | 5.47M | 8.53M | 14.65M | 18.25M |
| Stockholders Equity | 7.06M | 4.24M | 13.39M | 29.33M | 55.80M |
Cash Flow | |||||
| Free Cash Flow | -14.18M | -18.88M | -19.47M | -23.36M | -16.54M |
| Operating Cash Flow | -13.90M | -18.85M | -19.02M | -23.10M | -16.22M |
| Investing Cash Flow | -280.57K | 9.83M | 11.01M | 8.28M | -30.12M |
| Financing Cash Flow | 17.09M | 9.06M | -3.64M | 6.72M | 54.77M |
Imunon Technical Analysis
Negative
1.51
Price Trends
1.90
Negative
2.38
Negative
3.08
Negative
Market Momentum
-0.11
Positive
34.80
Neutral
30.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNN, the sentiment is Negative. The current price of 1.51 is below the 20-day moving average (MA) of 1.76, below the 50-day MA of 1.90, and below the 200-day MA of 3.08, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 34.80 is Neutral, neither overbought nor oversold. The STOCH value of 30.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMNN.
Imunon Risk Analysis
Imunon disclosed 4 risk factors in its most recent earnings report. Imunon reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Imunon Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $11.91M | -0.72 | -77.34% | ― | ― | 77.90% | |
49 Neutral | $4.83M | -0.09 | -99.39% | ― | ― | 95.40% | |
47 Neutral | $6.68M | -0.27 | -341.23% | ― | ― | 71.83% | |
45 Neutral | $144.21M | -1.74 | -116.86% | ― | -98.25% | 76.83% |
* Healthcare Sector Average
IMNN
Imunon
1.58
-6.04
-79.26%
KZIA
Kazia Therapeutics
12.41
3.73
42.97%
PHIO
Phio Pharmaceuticals
1.03
-1.32
-56.17%
GNPX
Genprex
4.75
-268.05
-98.26%
RNAZ
TransCode Therapeutics
4.22
-7.28
-63.30%
Imunon Corporate Events
Executive/Board Changes
Imunon Names Josh Blacher Interim Chief Financial Officer
Neutral
Jun 30, 2026
On June 29, 2026, Imunon announced that interim Chief Financial Officer Jeffrey Church, who has served in the role since January 2026, will retire effective July 1, 2026, with his departure attributed solely to retirement and no disagreements with...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Imunon Shareholders Expand Stock Incentive Plan, Back Governance
Positive
Jun 16, 2026
At its 2026 Annual Meeting of Stockholders held on June 16, 2026, Imunon shareholders approved an amendment to the company’s 2018 Stock Incentive Plan, adding 1,000,000 shares and raising the plan’s aggregate share limit to 1,265,004 s...
Business Operations and StrategyPrivate Placements and Financing
Imunon Secures $10 Million Non-Dilutive Structured Financing
Positive
Jun 4, 2026
On June 2, 2026, IMUNON entered into a securities purchase agreement with Streeterville Capital for a $10 million structured financing that closed on June 3, 2026, combining $2.5 million of non-convertible Series A preferred stock with $7.72 milli...
Business Operations and StrategyExecutive/Board Changes
Imunon Adopts Change-of-Control Severance Agreements for Executives
Positive
May 4, 2026
On May 1, 2026, Imunon, Inc. approved and entered into change-of-control agreements with CEO Stacy Lindborg, CMO Douglas Faller, and General Counsel Susan Eylward, setting severance protections if their employment ends under specified conditions a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.